Advertisement
New Zealand markets closed
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5959
    +0.0022 (+0.38%)
     
  • NZD/EUR

    0.5551
    +0.0005 (+0.10%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    82.76
    -0.05 (-0.06%)
     
  • GOLD

    2,337.40
    -1.00 (-0.04%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,093.36
    +52.98 (+0.66%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    17,985.47
    -103.23 (-0.57%)
     
  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • NZD/JPY

    92.6910
    +0.5760 (+0.63%)
     

Could Moderna and AstraZeneca's mRNA Heart Failure Drug Candidate Be a Winner?

Moderna (NASDAQ: MRNA) and AstraZeneca (NASDAQ: AZN) compete against each other in some markets with their respective COVID-19 vaccines. In this Motley Fool Live video recorded on Nov. 16, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Moderna's and AstraZeneca's mRNA candidate could be a winner.